Y. Shravan Kumar
Research Subjects
Y. Shravan Kumar has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Shirsat
Hon. Shri Babanrao Pachpute Vichardhara Trust’s Group of Institutions, Faculty of Pharmacy
1 shared publication Anup Lal Yadav
School of Engineering and Technology, CGC University
1 shared publicationDeepthi B
1 shared publicationHarika S
1 shared publication- Jayashree Prasad
MIT Art Design and Technology University
1 shared publication - L Pravalika1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by Springer Nature in Research Square
Decision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug- Loaded Microbubbles and Control Strategy Development
A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.
- 25 February 2026
- Published by Springer Nature in Research Square
Open AccessDecision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug- Loaded Microbubbles and Control Strategy Development
A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.
- 1 January 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (2) , 752-756
Formulation and evaluation of carvedilol sustained release capsules by semisolid matrix filling technique
The objective of the study was to prepare semisolid capsules of poorly water-soluble drug Carvedilol using a combination of technologies involving solid dispersion preparation and converting it into semisolid matrix filled in hard gelatin capsule. Different excipients like Gelucire44/14, poloxamer188, gelatin, PVPK30, PEG6000 were used. Fifteen capsule formulations were prepared and assessed for their release characteristics. Lipid matrix formulations prepared with increasing amount of polymer showed a substantial decrease in release rate of drug in case of poloxamer188Whereas gelucire 44/14, gelatin, PVPK30, and PEG6000 showed immediate release the mechanism of drug release from the test formulations were studied. The possible modification of carvedilol release kinetics by using poloxamer in the SSM was studied. results indicate that poloxamer188 is an appropriate carrier for the development of sustained release drug delivery systems and Gelucire44/14 a highly hydrophilic and lipophilic balance (HLB) excipient, acts as release enhancer in the different ratios studied. Among all the formulations Carvedilol formulation with poloxamer188 in the ratio of (1: 3) showed sustained release. Release kinetics studies were performed. The formulation with poloxamer in 1: 3 ratio follows first order and Higuchi order release kinetics governed by Fickian diffusion mechanism with R2 value 0.992.
- 1 January 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (2) , 752-756
Formulation and evaluation of carvedilol sustained release capsules by semisolid matrix filling technique
The objective of the study was to prepare semisolid capsules of poorly water-soluble drug Carvedilol using a combination of technologies involving solid dispersion preparation and converting it into semisolid matrix filled in hard gelatin capsule. Different excipients like Gelucire44/14, poloxamer188, gelatin, PVPK30, PEG6000 were used. Fifteen capsule formulations were prepared and assessed for their release characteristics. Lipid matrix formulations prepared with increasing amount of polymer showed a substantial decrease in release rate of drug in case of poloxamer188Whereas gelucire 44/14, gelatin, PVPK30, and PEG6000 showed immediate release the mechanism of drug release from the test formulations were studied. The possible modification of carvedilol release kinetics by using poloxamer in the SSM was studied. results indicate that poloxamer188 is an appropriate carrier for the development of sustained release drug delivery systems and Gelucire44/14 a highly hydrophilic and lipophilic balance (HLB) excipient, acts as release enhancer in the different ratios studied. Among all the formulations Carvedilol formulation with poloxamer188 in the ratio of (1: 3) showed sustained release. Release kinetics studies were performed. The formulation with poloxamer in 1: 3 ratio follows first order and Higuchi order release kinetics governed by Fickian diffusion mechanism with R2 value 0.992.
- 1 January 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (3) , 1601-1606
Formulation and evaluation of theophylline Lozenges
- 1 January 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (3) , 1601-1606
Formulation and evaluation of theophylline Lozenges
- 30 September 2019
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 12 (5) , 4865-4671
Formulation and Evaluation of Metoprolol Tartrate Sustained Release Matrix Tablets
The objective of the present work was to develop sustained release matrix tablets of Metoprolol tartrate using different polymers viz. Guar gum, Xanthan gum, Kondagogu gum and HPMC K100M. The release rates were modulated by combination of two different rates controlling material and triple mixture of two different rate controlling materials. After evaluation of physical properties of tablet, the in-vitro release study was performed in phosphate buffer pH 6.8 up to 12 hrs. Dissolution data was analyzed for release kinetics. It was observed that matrix tablets contained polymer Xanthan gum was successfully sustained the release of drug up to 12 hrs. Among all the formulations, F6 which contains 45 % of Xanthan gum, release of drug which follows zero order kinetics via, swelling, diffusion and the release profile of formulation F6 was compared with marketed product. The FTIR study revealed that there was no chemical interaction between drug and excipient.
- 30 September 2019
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 12 (5) , 4865-4671
Formulation and Evaluation of Metoprolol Tartrate Sustained Release Matrix Tablets
The objective of the present work was to develop sustained release matrix tablets of Metoprolol tartrate using different polymers viz. Guar gum, Xanthan gum, Kondagogu gum and HPMC K100M. The release rates were modulated by combination of two different rates controlling material and triple mixture of two different rate controlling materials. After evaluation of physical properties of tablet, the in-vitro release study was performed in phosphate buffer pH 6.8 up to 12 hrs. Dissolution data was analyzed for release kinetics. It was observed that matrix tablets contained polymer Xanthan gum was successfully sustained the release of drug up to 12 hrs. Among all the formulations, F6 which contains 45 % of Xanthan gum, release of drug which follows zero order kinetics via, swelling, diffusion and the release profile of formulation F6 was compared with marketed product. The FTIR study revealed that there was no chemical interaction between drug and excipient.
- 30 September 2017
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 10 (5) , 3836-3843
Formulation and Evaluation of Salbutamol Sulphate Sublingual Films
Salbutamol is a short-acting, selective beta-2-adrenergic receptor agonist used in treatment of asthma and COPD. In the present work, sublingual films of Salbutamol sulphate were developed with a view to enhance the patient compliance and provide quick onset of action. Salbutamol has a bioavailability of 53 - 60%. The goal of the study was to formulate sublingual films of Salbutamol sulphate to achieve a better dissolution rate and further improving the bioavailability of the drug. Sublingual films prepared by solvent casting method using film forming polymers HPMC-E5, HPMC-E15 and Maltodextrin in different ratios. The prepared batches of films were evaluated for the drug content, weight variation, film thickness, disintegration time and in vitro dissolution studies. Among all, the formulation B1 containing HPMC-E15 with a drug: polymer ratio (1:6) was found to be the best formulation which showed 98.36% of the drug release within 15 minutes and disintegration time 18 sec. This study shows the viability of developing sublingual films of salbutamol.
- 30 September 2017
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 10 (5) , 3836-3843
Formulation and Evaluation of Salbutamol Sulphate Sublingual Films
Salbutamol is a short-acting, selective beta-2-adrenergic receptor agonist used in treatment of asthma and COPD. In the present work, sublingual films of Salbutamol sulphate were developed with a view to enhance the patient compliance and provide quick onset of action. Salbutamol has a bioavailability of 53 - 60%. The goal of the study was to formulate sublingual films of Salbutamol sulphate to achieve a better dissolution rate and further improving the bioavailability of the drug. Sublingual films prepared by solvent casting method using film forming polymers HPMC-E5, HPMC-E15 and Maltodextrin in different ratios. The prepared batches of films were evaluated for the drug content, weight variation, film thickness, disintegration time and in vitro dissolution studies. Among all, the formulation B1 containing HPMC-E15 with a drug: polymer ratio (1:6) was found to be the best formulation which showed 98.36% of the drug release within 15 minutes and disintegration time 18 sec. This study shows the viability of developing sublingual films of salbutamol.
- 28 February 2015
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 8 (1) , 2723-2734
Formulation and Evaluation of Taste Masked Oral Disintegrating Tablets of Aripiprazole
Aripiprazole is an atypical antipsychotic agent used for treatment of schizophrenia, bipolar disorder and major depressive disorders. In the present work, oral disintegrating tablets of aripiprazole were developed to enhance the patient compliance and provide rapid onset of action. The efficacy of aripiprazole is mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5HT-1A receptors and antagonist activity at 5HT-2A receptors. It has a bitter taste and poor-solubility in water. Thus, the main objective of the study is to formulate taste masked oral disintegrating tablets of aripiprazole by using inclusion complex beta-cyclodextrin to achieve a better dissolution rate and further improving the bioavailability of the drug. Oral disintegrating tablets were prepared by direct compression method using super disintegrant like crospovidone, croscarmellose sodium, sodium starch glycolate and combinations of cros-povidone with croscarmellose sodium, and crospovidone with sodium starch glycolate in different concentrations. They were evaluated for the pre-compression parameters such as bulk density, compressibility, Hausner ratio and angle of repose. The prepared batches of tablets were evaluated for hardness, weight variation, thickness, friability, drug content, disintegration time, wetting time, in vitro dispersion time, and in vitro dissolution profile. All these parameters were found to be satisfactory. Among all, the formulation F15 containing crospovidone 5% + cros-povidone with croscarmellose sodium 5% was considered to be the optimum formulation, which released nearly 99% of the drug in 20 minutes with a disintegration time of 10. 20 seconds. These studies indicate the viability and benefits of oral disintegrating tablets of aripiprazole.
- 28 February 2015
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 8 (1) , 2723-2734
Formulation and Evaluation of Taste Masked Oral Disintegrating Tablets of Aripiprazole
Aripiprazole is an atypical antipsychotic agent used for treatment of schizophrenia, bipolar disorder and major depressive disorders. In the present work, oral disintegrating tablets of aripiprazole were developed to enhance the patient compliance and provide rapid onset of action. The efficacy of aripiprazole is mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5HT-1A receptors and antagonist activity at 5HT-2A receptors. It has a bitter taste and poor-solubility in water. Thus, the main objective of the study is to formulate taste masked oral disintegrating tablets of aripiprazole by using inclusion complex beta-cyclodextrin to achieve a better dissolution rate and further improving the bioavailability of the drug. Oral disintegrating tablets were prepared by direct compression method using super disintegrant like crospovidone, croscarmellose sodium, sodium starch glycolate and combinations of cros-povidone with croscarmellose sodium, and crospovidone with sodium starch glycolate in different concentrations. They were evaluated for the pre-compression parameters such as bulk density, compressibility, Hausner ratio and angle of repose. The prepared batches of tablets were evaluated for hardness, weight variation, thickness, friability, drug content, disintegration time, wetting time, in vitro dispersion time, and in vitro dissolution profile. All these parameters were found to be satisfactory. Among all, the formulation F15 containing crospovidone 5% + cros-povidone with croscarmellose sodium 5% was considered to be the optimum formulation, which released nearly 99% of the drug in 20 minutes with a disintegration time of 10. 20 seconds. These studies indicate the viability and benefits of oral disintegrating tablets of aripiprazole.
- 31 August 2013
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 6 (2) , 2087-2096
Formulation and Evaluation of Sumatriptan Succinate Fast Disintegrating Films and Tablets
Sumatriptan succinate is a 5-HT1B/1D receptor agonist which has well established efficacy in treating migraine. The main objective of the study was to formulate Oral Fast Disintegrating Films (ODF) and Oral Fast Disintegrating Tablets (ODT) to achieve a better dissolution rate and further improving the bioavailability of the drug. ODFs were prepared by solvent casting method using film forming polymers like HPMC – E15,5cps,50cps in different ratios & prepared batches of films were evaluated for the drug content, film thickness, disintegration time and in vitro dissolution studies. Among the prepared formulation F7 containing HPMC – 50cps (drug: polymer ratios = 1:1) was found to be best formulations which releases 98.2±1.1of the drug within 17±0.02 sec. ODTs prepared by direct compression method using in different concentrations of super-disintegrants. The prepared formulation T12 (combination of disintegrants) containing CP + CCS (6%) was considered to be the best formulation, which releases up to 100±0.38% of the drug in 23±0.75 sec, respectively. Based on these results, it is suggested that ODFs have faster disintegration time and drug release than ODTs.
- 31 August 2013
- Published by BSP Books Private Limited in International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN)
- Vol. 6 (2) , 2087-2096
Formulation and Evaluation of Sumatriptan Succinate Fast Disintegrating Films and Tablets
Sumatriptan succinate is a 5-HT1B/1D receptor agonist which has well established efficacy in treating migraine. The main objective of the study was to formulate Oral Fast Disintegrating Films (ODF) and Oral Fast Disintegrating Tablets (ODT) to achieve a better dissolution rate and further improving the bioavailability of the drug. ODFs were prepared by solvent casting method using film forming polymers like HPMC – E15,5cps,50cps in different ratios & prepared batches of films were evaluated for the drug content, film thickness, disintegration time and in vitro dissolution studies. Among the prepared formulation F7 containing HPMC – 50cps (drug: polymer ratios = 1:1) was found to be best formulations which releases 98.2±1.1of the drug within 17±0.02 sec. ODTs prepared by direct compression method using in different concentrations of super-disintegrants. The prepared formulation T12 (combination of disintegrants) containing CP + CCS (6%) was considered to be the best formulation, which releases up to 100±0.38% of the drug in 23±0.75 sec, respectively. Based on these results, it is suggested that ODFs have faster disintegration time and drug release than ODTs.